Sublocade (buprenorphine) and Vivitrol (naltrexone) are prescription drugs used to treat opioid use disorder. Vivitrol is also prescribed for alcohol use disorder. Both drugs come as an injection ...

If you’re considering treatment for opioid use disorder (OUD), your doctor may recommend Sublocade. It’s prescribed as part of a complete treatment program to manage opioid addiction in adults with ...

Sublocade (buprenorphine) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat opioid use disorder in adults, as part of a complete treatment ...

Sublocade (buprenorphine) and Suboxone (buprenorphine/naloxone) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat opioid use disorder (OUD).

Please provide your email address to receive an email when new articles are posted on . The FDA approved label changes that include a rapid initiation protocol and alternative injection sites. The ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability. 1 ...

For my penultimate Barchart article in 2025, I wanted to revisit Indivior (INDV), a Virginia-based developer of opioid ...

Sublocade is intended for use as part of a complete treatment program that includes counseling and psychosocial support. Sublocade is intended for use as part of a complete treatment program that ...

Indivior PLC announced that it was added to the S&P SmallCap 600 index on December 22, 2025, following earlier inclusions in the S&P 1000 and the S&P Pharmaceuticals Select Industry Index and ...

Investing.com -- Indivior Plc’s shares have already climbed about 200% in 2025, and Jefferies says the next phase of the story will hinge on how the company frames its 2026 outlook rather than on ...